The first small RCT shows a positive effect of GlyNAC on multiple aging-related outcomes, from glutathione replenishment to physical function and inflammation. However, the research is still at an early stage: the only controlled study included just 24 participants over 16 weeks. That makes the results promising but not yet sufficiently substantiated to base firm recommendations on; larger and longer RCTs are needed.
GlyNAC is a combination of two amino acids: glycine and N-acetylcysteine (NAC). Together they form the building blocks for glutathione, one of the most important antioxidants in the human body. As we age, glutathione production declines, which is associated with greater oxidative damage to cells, poorer mitochondrial function, and a higher likelihood of age-related conditions. That pattern is described in a review article1, which also reports that healthy older adults with excellent health actually have higher glutathione levels than comparable peers of the same age.
The most robust human study is a placebo-controlled RCT involving 24 older participants (12 GlyNAC, 12 placebo) over 16 weeks2. In that study, GlyNAC improved the glutathione deficit, reduced markers of oxidative stress, restored mitochondrial fatty acid oxidation, and at the same time improved physical function: walking speed, muscle strength, and endurance as measured by a 6-minute walk test. In addition, inflammatory markers, insulin resistance, and signs of poor vascular endothelial function all declined in the GlyNAC group compared with placebo. With only 24 participants, these are positive but still early results.
A second, smaller pilot study with just 8 participants and no control group3 reported improvements after 24 weeks of GlyNAC in even more areas: cognition, body composition, and reduced DNA damage. An important detail: the benefits diminished after participants stopped supplementation for 12 weeks. Without a control group, however, it cannot be ruled out that other factors played a role, which is why this evidence is considered limited.
Regarding safety: in both studies GlyNAC was well tolerated by older participants and no serious adverse effects were reported2,3. That is a positive sign for practical use, but again the study populations were small and the follow-up periods short.
Beyond aging, GlyNAC has also been described as a possible adjunct strategy in HIV, where a similar pattern of glutathione deficiency occurs. The evidence base for that application is still at an earlier stage and is methodologically heterogeneous4, making conclusions specific to that group premature. For further use in aging, larger and longer RCTs are necessary before firm recommendations can be made.
Based on one RCT (n=24, PMID 35975308), one open-label pilot study without a control group (n=8, PMID 33783984), one review article on glutathione and aging (PMID 37683986), and one review article on HIV (PMID 41754089). No meta-analyses are available. The total RCT population is small.